Evidence map›Paper›PMID 26136935›Full record

ArticleExperimental and therapeutic medicine2015

Frequency of

Silvina Noemi Contreras-Capetillo, Hugo Leonid Gallardo Blanco, Ricardo Martin Cerda-Flores, José Lugo-Trampe, Iris Torres-Muñoz, Antonio Bravo-Oro, Carmen Esmer, Laura Ella Martínez DE Villarreal

Abstract read
In one paragraph

Article in Experimental and therapeutic medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Silvina Noemi Contreras-CapetilloDepartment of Genetics, Dr. Hideyo Noguchi Regional Research Center, Autonomous University of Yucatan, Mérida, Yucatán CP 97225, Mexico.
Hugo Leonid Gallardo BlancoDepartment of Genetics, School of Medicine, Monterrey, Nuevo León CP 64460, Mexico.
Ricardo Martin Cerda-FloresSchool of Nursing, Autonomous University of Nuevo León, Monterrey, Nuevo León CP 64460, Mexico.
José Lugo-TrampeDepartment of Genetics, School of Medicine, Monterrey, Nuevo León CP 64460, Mexico.
Iris Torres-MuñozDepartment of Genetics, School of Medicine, Monterrey, Nuevo León CP 64460, Mexico.
Antonio Bravo-OroNeuropediatrics, Central Hospital 'Dr. Ignacio Morones Prieto', San Luis Potosí CP 78240, Mexico.
Carmen EsmerDepartment of Genetics, Central Hospital 'Dr. Ignacio Morones Prieto', San Luis Potosí CP 78240, Mexico.
Laura Ella Martínez DE VillarrealDepartment of Genetics, School of Medicine, Monterrey, Nuevo León CP 64460, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Individuals who suffer from spinal muscular atrophy (SMA) exhibit progressive muscle weakness that frequently results in mortality in the most severe forms of the disease. In 98% of cases, there is a homozygous deletion of the survival of motor neuron 1 (

Indexed as

heterozygous carriershypotonic syndromeneuromuscular diseasesSMN1 genespinal muscular atrophy type I

Identifiers

PMID26136935
PMCPMC4473530

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.